Benzinga | Aug 16, 2021 08:11AM EDT

Exelixis And Invenra Expand Collaboration To Discover And Develop Novel Biologics In Oncology

Exelixis, Inc. (NASDAQ:EXEL) and Invenra, Inc. today announced that they have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. The augmented partnership builds on the two companies' ongoing collaboration and license agreement to discover and develop mono-specific and multi-specific antibodies for incorporation into novel biologics to treat cancer, which was originally announced in May 2018 and expanded in October 2019.